News &

February 25, 2019

Robert Gallotto

Robert Gallotto serves as President and chief executive officer of Synspira Therapeutics. Mr. Gallotto is an experienced pharmaceutical executive, with a 30-year record of building companies focused in cystic fibrosis and other rare diseases. Prior to joining Synspira, Mr. Gallotto was the co-founder and served as President of Alcresta Therapeutics, a company focused on developing products for cystic fibrosis and other rare diseases. Mr. Gallotto built the company from an idea to the successful launch of its first product, RELiZORB, a novel medical device awarded the 2016 Medical Device Design Excellence Gold Medal Award. Mr. Gallotto has been involved with several collaborations with the CF Foundation over the past 20 years and is the inventor of numerous issued patents. Mr. Gallotto also served as co-founder and chief operating officer of Allena Pharmaceuticals. Prior to Alcresta and Allena, Mr. Gallotto served as chief business officer of Alnara Pharmaceuticals, until the company was acquired by Eli Lilly. Mr. Gallotto also served as vice president of strategic planning, business and commercial development for Altus Pharmaceuticals. Before joining Altus, Mr. Gallotto served in various positions in sales and marketing, business development and product management with companies such as Biogen, Ares-Serono, Sage BioPharma and The Upjohn Company. Mr. Gallotto holds a B.S. in biology from Stonehill College.